Health Care
Conneqt Health Limited (CQT)
Conneqt Health Limited is an Australian digital health company providing an integrated platform that connects consumers, healthcare providers, and payers. Its core products include MyHealth1st, an online healthcare booking marketplace, and Visionflex, a telehealth hardware and software solution. The company aims to improve access to healthcare and streamline administrative processes for clinics, governments, and corporate clients across Australia.
Market Cap
A$28M
Shares on Issue
N/A
Price Chart
AI Analysis
With a micro-cap valuation of approximately A$28M, Conneqt Health is a speculative growth company focused on expanding its market share in the Australian digital health sector. The company's recent performance has centered on growing its recurring revenue base through client acquisitions for its SaaS platforms and managing cash burn, as detailed in its quarterly Appendix 4C reports. As CQT is not yet profitable, key investor metrics are annual recurring revenue (ARR), customer growth, and the pathway to cash flow breakeven, rather than traditional earnings-based valuations.
The growth outlook for CQT is heavily reliant on the broader adoption of telehealth and digital patient management systems in Australia. Upcoming catalysts could include the announcement of new large-scale enterprise or government contracts, particularly for its Visionflex telehealth or GoBookings platforms. The company's strategic direction involves deepening its integration with existing major partners like Medibank and Bupa, expanding its service offerings, and achieving operating leverage as its user base scales.
Bull Case
- • Strong industry tailwinds from the structural shift towards telehealth and digital healthcare solutions post-pandemic.
- • Established partnerships with major health industry players like Medibank and government agencies provide credibility and key distribution channels.
- • High potential for operating leverage if the platform achieves critical mass, leading to significant margin expansion on a largely fixed cost base.
Bear Case
- • Significant competition from other digital health platforms and booking systems, including larger, better-funded rivals.
- • A history of operating losses and cash burn necessitates reliance on capital markets, creating potential dilution risk for existing shareholders.
- • Execution risk in scaling the business and the potential loss of a major enterprise partner could severely impact revenue and investor confidence.
Recent Announcements
December Quarterly Activities Report
🚨 Price SensitiveCQT, a commitments test entity on ASX, has reported its quarterly activities for December with specific financial results and strategic updates relevant to investors.
December Quarterly Appendix 4C
🚨 Price SensitiveThe ASX announcement for company CQT, a Commitments Test Entity (CTE), details its quarterly financial performance and compliance status in the December report. Investors should review this document to assess current standing and future prospects of their investment.
FAQs
What does CQT do?
Conneqt Health provides a suite of digital health software and services in Australia. Its main products are MyHealth1st for online appointment bookings and Visionflex, a comprehensive telehealth platform that includes specialised hardware and software for remote medical consultations.
Is CQT a good investment?
CQT is a speculative, high-risk investment. Its potential lies in its ability to capture a larger share of the growing digital health market and scale its platform to profitability. However, risks include intense competition, the need for future funding, and the challenges of executing its growth strategy in a competitive landscape.
What drives CQT's share price?
The share price is primarily driven by contract announcements with new enterprise or government clients, quarterly cash flow reports (Appendix 4C) indicating revenue growth and cash burn, and overall market sentiment towards early-stage, speculative technology stocks.
Key Metrics
Related Stocks
Health Care
CSLCSL Ltd
A$181.24
-27.3% 1Y
CSL is a global biotechnology leader focused on plasma-derived therapies, vaccines, and specialty biologics.
Health Care
PNVPolynovo Ltd
A$0.99
-13.1% 1Y
Polynovo manufactures innovative wound care products used in burns, trauma, and reconstructive surgery.
Health Care
1ADAdalta Limited
A$0.01
-25.6% 1Y
Adalta Limited is a clinical-stage biotechnology company developing its proprietary i-body technology platform for treating a range of diseases. Based in Australia, its lead product candidate, AD-214, is being developed to treat Idiopathic Pulmonary Fibrosis (IPF) and other human fibrotic diseases.